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6 Summary 
Adenoviral infections of neurons, glial cells and ventricle ependyma 
cells in situ as a prospect for an in-vivo genetic therapeutical  
approach in neurodegenerative diseases 
In this study the characteristics of transduction as well as the efficacy of transduction 
of different stem cell populations are being investigated by using a 3rd generation 
adenoviral vector, a so called gutless adenoviral vector. 
These cells include glial restricted precursor cells of rat and human origin as well as 
murine embryonic stem cells. 
As representatives for an adult stem cell population the possibility of a transduction 
of the autologous available mesenchymal stem cells deriving from the human bone 
marrow stroma are examined. 
For cell transduction, vectors with different reporter sequences are applied, resulting 
in the possibility of measuring the transduction success after infection by the 
transgene expression. 
The reporter genes include the green fluorescent protein (GFP), the LacZ (ß-
galactosidase) as well as the human secreted placenta alkaline phosphatase 
(SEAP). Applying increasing numbers of infectious particles (10, 50 and 100 MOI) a 
concentration-dependent transduction rate can be ascertained in the different 
investigated cell populations. The highest transduction rates are achieved in 
association with the glial restricted neural precursor cells. 
Following infection of the neural differentiated embryonic stem cells similarly a 
tendency towards a preferred transduction of glial differentiated cells is observed. 
The use of adult stem cells also results in transduction rates up to 85%. 
In further investigations glial restricted neural precursor cells, after having been 
infected with the adenoviral vector are injected into the striatum of adult rats. This 
procedure was performed in order to test the possibility of an ex-vivo gene 
therapeutical use in association with glial cells as possible carrier cells. The results 
show that the transduced cells are integrated into the receiving tissue and during the 
investigation period of six weeks only migrate into the surrounding tissue to a 
restricted extent. 
At a closer look the injected cells show normal characteristics of differentiation along 
the glial cell linage as it has been described for astrocytes in-vivo. 
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The second part of this study focuses on the direct vector injection into the central 
nervous system. Therefore the 3rd generation adenoviral vector is injected into 
different brain areas. Using immunohistochemical investigations using antibodies 
against NeuN and GFAP it can be shown that after injection into the striatum 
analogous to the situation in-vitro a preferential transduction of astrocytes is 
achieved. Within this brain compartment a diffusion of the vector up to a distance of 
1000 µm from the injection site can be determined. 
 Following injection of vector particles into the corpus callosum, a vector distribution 
within the entire fibre tract of the white substance including the contralateral 
hemisphere is observed. 
With these results it can be shown that the allocation of the vector is dependent on 
the structure and features of the receiving tissue. 
Injecting the adenoviral vector into the cerebrospinal fluid results in transgene 
expression (GFP, LacZ and SEAP) in the ependymal cells surrounding the entire 
ventricle.
These results suggest that the vector distributes within the cerebrospinal fluid and 
therefore would result in a generalized transduction of ependymal cells. 
After installing a permanent catheter in the lateral ventricle cerebrospinal fluid may 
be removed in a continuous manner in order to analyse/evaluate the marker enzyme 
SEAP.
Using a luminometric screening procedure the enzyme SEAP can be demonstrated 
up to a period of 42 days following vector injection into the cerebrospinal fluid. 
Summarizing the results, the use of an adenoviral vector at least under experimental 
circumstances might be a pioneer therapeutical option for diseases of the central 
nervous system. 
